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Abstract
Background: The aim of this study was to investigate the characteristics of prostate cancer
patients who were diagnosed at repeat biopsy and compare them to non-cancerous patients or
patients who were diagnosed at initial biopsy.
Methods: We carried out a retrospective analysis of clinical and pathological data from 576
patients, which included data on the period of time from radical prostatectomy to biochemical
failure.
Results: Cancer was diagnosed in 191 (33%) of 576 patients at initial biopsy and in 23 (18%) of 127
patients who underwent a repeat biopsy. Cut-off values of 0.80 and 0.30 for prostate specific
antigen velocity (PSAV) and prostate specific antigen density (PSAD), respectively, were
determined using ROC curve analysis. Based on these values, PSAV and PSAD were able to predict
94% (46 of 49) of negative repeat biopsies, indicating that these patients had undergone
unnecessary repeat biopsies. Although the patients who were diagnosed at repeat biopsy had a
higher rate of organ-confined tumor than those who were diagnosed at initial biopsy (73% and 44%,
respectively; P = 0.041), there were no differences in the recurrence rate or the duration of
biochemical failure-free survival between the two groups.
Conclusion: PSAV and PSAD may be useful indicators of the results of repeat biopsies. Although
prostate cancer that was diagnosed at repeat biopsy was associated with a more favorable
pathological profile, it was not associated with a better outcome after radical prostatectomy.
Background
Due to the wide-spread use of prostate specific antigen
(PSA) screening, there has been an increasingly large
number of men with elevated PSA and negative prostate
biopsy [1]. A high percentage of these men undergo
unnecessary repeat biopsy. In general, a repeat biopsy is
indicated by increasing PSA levels, increased PSAD and
PSAV, low free PSA ratio, and previous pathological find-
ings, such as high grade intraepithelial neoplasia. How-
ever, there is currently no definitive or reliable predictor of
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repeat biopsy outcome. It is also largely unknown
whether there are differences in the clinical and biological
characteristics of prostate cancer that is detected at repeat
biopsy as compared to initial biopsy [1].
Miyake et al. have reported that there was no significant
difference in the pathological stage or volume of cancer
diagnosed at initial biopsy as compared to repeat biopsy
[2]. In contrast, Lopes-Corona et al. suggested that pros-
tate cancer that is diagnosed at repeat biopsy is associated
with favorable pathological findings at the time of radical
prostatectomy. However, they also reported that there is a
similar recurrence rate for cancers that are detected at
repeat biopsy and initial biopsy [3]. These results suggest
that the detection of prostate cancer at a repeat biopsy
does not predict a favorable outcome. Rather, several
studies have indicated that the number or percentage of
positive biopsy cores may be an important predictor of a
favorable outcome [4-7].
In the current study, we have assessed several conven-
tional clinical variables associated with positive and neg-
ative repeat biopsies in order to identify a potential
predictor of repeat biopsy outcome. We also compared
the clinical and pathological characteristics and outcome
associated with prostate cancer that was detected at initial
and repeat biopsies.
Methods
Patient characteristics
Five hundred seventy-six (576) patients that were sus-
pected of having prostate cancer underwent transrectal
prostate needle biopsies from 1998 to 2006 at Akita Uni-
versity Medical Center. Of the patients who had a negative
initial biopsy, 127 underwent a repeat biopsy. Six- or ten-
transrectal biopsy cores were taken from the peripheral
zone of the prostate using an 18-gauge needle biopsy gun
under transrectal ultrasound guidance during the time
periods of 1998–2003 or 2004–2006, respectively. For all
patients with prostate cancer, clinical and pathological
classifications were determined according to the World
Health Organization criteria, the Gleason's histological
grading, and the Tumor-Node-Metastatic system [8,9].
Biochemical Failure
Biochemical failure was defined as a PSA level of greater
than 0.2 ng/mL [10]. Patients were routinely seen for fol-
low-up 1 month after prostatectomy, and every 6 to 12
months thereafter.
Statistical analysis
The clinical values represent the means ± standard devia-
tion (SD), and differences between groups were analyzed
using the unpaired Student's t-test, Kruskal Wallis test, or
the Mann-Whitney U test if the group variances were
equal or non-normally distributed. Differences in clinical
and pathological factors between groups were analyzed by
the chi-square test. Receiver operating characteristic
(ROC) curves were constructed by plotting sensitivity ver-
sus the false-positive rate. Biochemical failure-free sur-
vival time was calculated from the date of radical
prostatectomy to the date of biochemical recurrence. Bio-
chemical failure-free survival was estimated using the
Kaplan-Meier method and differences in survival were
analyzed using the logrank test. All data was entered into
an Access database and analyzed by Excel 98 and SPSS
(version 10.0J, SPSS Inc.) software programs. A probabil-
ity (P) of < 0.05 was considered statistical significant.
Results
Clinical and pathological characteristics of patients with 
positive and negative repeat biopsies
The number of cores taken at repeat biopsy was greater
than initial biopsy (7.31 ± 2.04 and 8.57 ± 2.11, respec-
tively; P = 0.0034). Cancer was diagnosed in 191 of 576
patients (33%) at initial biopsy, and 23 of 127 patients
(18%) who underwent repeat biopsy. The positive rate of
diagnosis at initial biopsy was significantly higher than at
repeat biopsy in our analysis (P = 0.042). There were no
significant differences in age (72.5 ± 7.2 and 69.5 ± 7.2, P
= 0.085), serum PSA level (12.6 ± 8.6 and 10.5 ± 7.5, P =
0.50), prostate volume (30.2 ± 23.6 and 39.7 ± 21.0, P =
0.15), PSAD (0.51 ± 0.43 and 0.34 ± 0.35, P = 0.13), PSAV
(2.6 ± 6.2 and 0.83 ± 6.2, P = 0.16), or number of cores
taken at repeat biopsy (8.6 ± 2.1 and 8.3 ± 2.3, P = 0.43)
between patients who had positive and negative repeat
biopsies, respectively. In addition, although we per-
formed a multivariate logistic regression analysis that con-
trols for this variable, we could not find a significant
difference in these values between them.
Analysis of PSA-related variables in patients with positive 
and negative results at repeat biopsy
We next examined the predictive value of PSAV and PSAD
for repeat biopsy outcome. Using ROC curve analyses, we
determined a cut-off value of 0.80 ng/ml/year and 0.30
ng/ml2 for PSAV and PSAD, respectively (Figure 1). Based
on this value, the sensitivity and specificity of PSAV for
predicting a positive repeat biopsy was 78% and 63%,
respectively (P = 0.0004, Table 1). Based on a cut-off value
of 0.30 ng/ml2, the sensitivity and specificity of PSAD was
61% and 67%, respectively (P = 0.12, Table 1). The specif-
icity and positive predictive value (PPV) of the combina-
tion of > 0.80 ng/ml/year PSAV and > 0.30 ng/ml2 PSAD
were 86% and 44%, respectively (Table 1). Using these
cut-off values, 44% (12 of 27) of patients would have
been predicted to have a positive repeat biopsy. For
patients with either > 0.80 ng/ml year PSAV or > 0.30 ng/
ml2 PSAD, the sensitivity and negative predictive value
(NPV) were 87% and 94%, respectively (Table 1), andBMC Urology 2008, 8:14 http://www.biomedcentral.com/1471-2490/8/14
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44% (46 of 127) of patients would have avoided a repeat
biopsy. However, 13% (3 of 23) of patients with prostate
cancer would have been missed.
Clinical and pathological characteristics of patients 
diagnosed with prostate cancer at initial and repeat biopsy
We next compared the clinical and pathological character-
istics of patients who were diagnosed with prostate cancer
an initial or repeat biopsy. In order to avoid the selection
bias, twenty-nine of the patients with distant metastasis,
who were diagnosed at initial biopsy, were excluded in
this analysis. As shown in Table 2A, patients who were
diagnosed with prostate cancer at a repeat biopsy had sig-
nificantly higher rates of non-palpable and organ-con-
fined disease than patients who were diagnosed at an
initial biopsy (Table 2A). Ninety-three and 9 patients who
were diagnosed at initial biopsy and seventeen and 2
patients who were diagnosed at repeat biopsy underwent
radical prostatectomy and local external beam radiation
therapy, respectively. Among these patients, the clinical
and pathological variables of 72 patients diagnosed at ini-
tial biopsy and 15 patients diagnosed at repeat biopsy,
ROC curves for PSAV and PSAD Figure 1
ROC curves for PSAV and PSAD. Receiver operating characteristic (ROC) curves were constructed by plotting sensitivity 
versus the false-positive rate using SPSS software.
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Table 1: Prediction of repeat biopsy results by PSAD and PSAV
Cancer
(n = 23)
Non-Cancer
(n = 104)
P sensitivity specificity PPV NPV
PSAV (ng/ml year) 0.0004 78% 63% 32% 93%
≥ 0.80 18 (78%) 39
(37%)
<0.80 5 (22%) 65
(63%)
PSAD (ng/mL2) 0.12 61% 67% 29% 89%
≥ 0.30 14 (61%) 34
(33%)
<0.30 9 (39%) 70
(67%)
PSAV ≥ 0.80 and PSAD ≥ 0.30 12 (52%) 15
(14%)
6.2 × 10-5 52% 86% 44% 89%
PSAV ≥ 0.80 and PSAD < 0.30 6 (26%) 24
(23%)
PSAV < 0.80 and PSAD ≥ 0.30 2 (9%) 19
(18%)
PSAV < 0.80 and PSAD < 0.30 3 (13%) 46
(44%)
0.0054 87% 44% 26% 94%
Abbreviations: PSA, prostate specific antigen; PSAD, PSA density; PSAV, PSA velocity; PPV, positive predictive value; NPV, negative predictive value.BMC Urology 2008, 8:14 http://www.biomedcentral.com/1471-2490/8/14
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who underwent radical prostatectomy without neoadju-
vant or adjuvant therapy, were compared (Table 2B). We
then compared the post-radical prostatectomy clinical
and pathological variables of patients who were diag-
nosed at initial and repeat biopsy. The mean period of fol-
low-up for patients who were diagnosed at initial and
repeat biopsy was 35 ± 26 (range 1 to 105) and 33 ± 22
(range 2 to 78) months, respectively. This difference was
not statistically significant (P = 0.68). There was signifi-
cantly more organ-confined disease detected at repeat
biopsy than at initial biopsy (P = 0.041, Table 2B). How-
ever, the rate of biochemical failure and the duration of
biochemical failure-free survival were not different
between the two groups (Figure 2A). These results sug-
gested that prostate cancer patients who are diagnosed at
a repeat biopsy do not have better outcomes than those
diagnosed at an initial biopsy, although the patients diag-
nosed at repeat biopsy had more favorable pathological
findings in the tissues that were removed by radical pros-
tatectomy. However, it is worth noting that the number of
patients analyzed in this study was not sufficient to make
this a conclusive finding.
Clinical and pathological characteristics of patients 
diagnosed with prostate cancer with one positive core, or 
two or more positive cores at biopsy
To determine whether the number of positive cores
obtained by biopsy was clinically significant, we com-
pared the clinical and pathological characteristics of
patients following radical prostatectomy who had one
positive core or two or more positive cores at biopsy. The
mean period of follow-up for patients with one positive
core and those with two or more positive cores was 31 ±
22 (range 1 to 98) and 37 ± 22 (range 1 to 105) months,
respectively. This difference was not statistically signifi-
cant (P = 0.45). Compared to patients who had two or
more positive cores, patients who had only one positive
core had significantly lower serum PSA levels, less patho-
logical organ-confined disease, and a lower rate of posi-
tive perineural infiltration and lymph duct invasion
(Table 3). However, the rate of biochemical failure and
duration of biochemical failure-free survival were not dif-
ferent between the two groups (Figure 2B). These results
indicated that the number of positive cores at biopsy is
not a good predictor of disease progression following rad-
ical prostatectomy.
Discussion
Several studies have been performed, mainly in Western
countries, to identify the risk factors for cancer in men
undergoing repeat prostate biopsy [11-13]. Borboroglu et
al. demonstrated that the only statistically significant pre-
dictor of a positive repeat biopsy was PSAV (P < 0.001).
Prostate cancer was detected in 64% of men with a PSAV
of 1 ng/ml or higher in extensive transrectal ultrasound
guided prostate biopsies (average of 22.5 cores) [11].
Djavan et al. have suggested that percent-free PSA was the
most accurate predictor of prostate cancer in settings
where a repeat biopsy was performed [12]. The authors
carried out a large retrospective study, and concluded that
repeat biopsies should be performed in patients with a
percent free PSA of less than 30% or a transition zone
Biochemical failure-free survival curves after radical prostatectomy Figure 2
Biochemical failure-free survival curves after radical prostatectomy. Biochemical failure-free survival curves for 
patients whose cancer was detected at an initial biopsy and a repeat biopsy (A). Biochemical failure-free survival curves for 
patients with one positive core and two or more positive cores at biopsy (B).
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PSAD of 0.26 ng/ml2  or greater [12]. Ouyang et al.
reported that the presence of atypia at initial biopsy is a
strong predictor of malignancy in subsequent biopsies
[13]. On the other hand, in a Japanese study, Park et al.
reported that total PSA, PSAD, PSAV, digital rectal exami-
nation, and TRUS findings were independent predictors
of a positive repeat biopsy [14]. Despite these data, there
is currently no standard set of criteria governing the per-
formance of repeat biopsies following a negative initial
biopsy in Japan or in Western countries. In the current
study, we have carried out a retrospective analysis of clin-
ical and pathological data on positive and negative repeat
biopsies in order to identify predictors of repeat biopsy
outcome. Based on an ROC curve analysis, we determined
cut-off values for PSAV and PSAD of 0.80 ng/ml/year and
0.30 ng/ml2, respectively. When at least one of these crite-
ria was satisfied, we predicted 87% (20 of 23) of positive
repeat biopsies. We also determined that 94% (46 of 49)
of patients who had PSAV and PSAD values that were
below the cut-off value underwent unnecessary repeat
biopsies. Furthermore, the use of PSAV and PSAD criteria
would have spared 44% (46 of 127) of patients from
undergoing a repeat biopsy (Table 1). These results war-
rant additional studies to identify other variables that can
Table 2: Characteristics of prostate cancer
A Clinical characteristics of prostate cancer diagnosed at repeat and initial biopsy.
Cancer at repeat biopsy (n = 23) Cancer at initial biopsy (n = 162) P
Patient age* 72.0 ± 5.7 71.5 ± 6.8 0.670
PSA (ng/ml)* 12.6 ± 8.6 27.0 ± 38.8 0.205
Gleason score* 6.3 ± 2.0 7.11 ± 1.59 0.150
No. of positive cores* 2.6 ± 2.2 3.33 ± 2.25 0.204
cT 0.005
T1a-c 18 (78%) 79 (49%)
T2a-c 5 (22%) 61 (37%)
T3a,b 0 (0%) 16 (10%)
T4 0 (0%) 6 (4%)
cN 0.059
N0 23 (100%) 142 (79%)
N1, N2 0 (0%) 20 (21%)
B Pathological characteristics of prostate cancer diagnosed at repeat biopsy and initial biopsy at the time of radical prostatectomy.
Cancer at repeat biopsy (n = 15) Cancer at initial biopsy (n = 72) P
Patient age* 72.3 ± 6.4 68.5 ± 5.5 0.042
PSA level* 14.3 ± 9.5 16.4 ± 24.9 0.59
Gleason score* 7.2 ± 1.4 7.1 ± 1.7 0.81
Pathological factor
≤ pT2b 11 (73%) 32 (44%) 0.041
≥ pT3a 4 (27%) 40 (56%)
pN0 14 (93%) 67 (93%) 0.97
pN1 1 (7%) 5 (7%)
cap (+) 4 (27%) 32 (44%) 0.20
pn (+) 6 (40%) 37 (51%) 0.42
sv (+) 1 (7%) 12 (17%) 0.32
Biochemical failure 4 (27%) 26 (36%) 0.48
*Data indicates the means ± SD.
#Biochemical failure represents the number of the patients, who were diagnosed as biochemical failure.
Abbreviations: PSA, prostate specific antigen; cap(+), positive for capsular invasion; pn(+), positive for perineural invasion; sv(+), positive for seminal 
vesicle invasion.BMC Urology 2008, 8:14 http://www.biomedcentral.com/1471-2490/8/14
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be used in conjunction with PSAV and PSAD to predict
the results of a repeat biopsy, and decrease the number of
needless repeat biopsies performed.
We also carried out a retrospective analysis of the clinical
and pathological characteristics and outcomes of patients
who were diagnosed at initial and repeat biopsies. Miyake
et al. demonstrated that there were no significant differ-
ences in the final pathological features of prostate cancers
that were detected at initial and repeat biopsies [2].
Although the authors did not analyze the outcome of
patients who were diagnosed at repeat biopsy, they specu-
lated that the biological behavior of the tumors that are
detected at initial and repeat biopsies may be similar. In
the current study, we found that patients who were diag-
nosed at a repeat biopsy had a significantly lower patho-
logical T-stage than those who were diagnosed at an initial
biopsy. However, the outcome after radical prostatectomy
was similar between the two groups (Figure 2A). We also
found that the number of positive cores at biopsy was not
predictive of outcome after radical prostatectomy (Figure
2B).
There have been several recent studies evaluating the rate
or duration of biochemical recurrence-free survival after
radical prostatectomy in patients who are diagnosed at
repeat biopsy. The largest retrospective study was carried
out by Lopez-Corona et al. [3]. The authors found that
cancer was diagnosed in 1,042 patients at an initial biopsy
and 315 at a repeat biopsy. Patients who were diagnosed
at repeat biopsies and underwent radical prostatectomy
had a higher rate of clinical T1c stage cancer and organ-
confined disease than patients who were diagnosed at an
initial biopsy (P  < 0.0001) [3]. However, despite the
appearance of more favorable pathological features in
tumors that were detected at a repeat biopsy, there was no
difference in biochemical recurrence rate [3]. Steiner et al.
demonstrated that when prostate cancer was diagnosed at
a repeat biopsy, a negative result at the initial needle
biopsy was predictive of a lower pathologic stage and
grade, as well as smaller tumor volume [15]. However,
patients who were diagnosed at a repeat biopsy did not
have more favorable outcomes after radical prostatec-
tomy. Our results agree with these previous studies, and
indicate that patients who are diagnosed at a repeat
biopsy include those with clinically insignificant and
organ-confined cancer, and those with treatment delay.
To our knowledge, this is the first study to demonstrate
that biochemical recurrence-free survival after radical
prostatectomy is similar in an Asian population of pros-
tate cancer patients who were diagnosed at initial or
repeat biopsies, similar to Caucasian populations.
The average number of cores per biopsy increased over the
period of time examined in the current study, from 6 cores
(between 1998 and 2003) to 10 cores (between 2004 and
2006). In addition, in the later period, there were more
patients diagnosed with prostate cancer at a repeat biopsy
(90/191 positive initial biopsy, 21/23 positive repeat
biopsies). These variables represent a potential for bias in
the current study, in terms of both the pathological fea-
tures of the tumor and prognosis. However, our results
warrant additional comprehensive analyses of patients
that are diagnosed with prostate cancer at repeat biopsies.
Table 3: Clinical and pathological characteristics of patients who underwent radical prostatectomy with one positive core, and two or 
more positive cores at biopsy
One positive core (n = 31) Two or more positive cores (n = 56) P
Age* 69.1 ± 5.6 68.8 ± 5.2 0.67
PSA* 12.5 ± 9.4 15.2 ± 14.0 0.021
Gleason score* 6.8 ± 1.6 7.3 ± 1.6 0.20
No. of positive cores* 1 3.7 ± 1.9 1.3 × 10-16
Pathological factor 0.038
≤ pT2b 21 (57%) 25 (44%)
≥ pT3a 10 (43%) 31 (56%)
pN0 30 (97%) 51 (91%) 0.31
pN1 1 (3%) 5 (9%)
cap (+) 10 (32%) 28 (44%) 0.11
pn (+) 8 (26%) 35 (51%) 0.0001
sv (+) 2 (7%) 12 (17%) 0.069
PSA failure 10 (32%) 20 (36%) 0.75
*Data represents the means ± SD.
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Conclusion
We have shown that a PSAV of ≥ 0.80 ng/ml/year and a
PSAD of ≥ 0.30 ng/ml2may be useful criteria for predicting
the result of a repeat biopsy, although in the current anal-
ysis, a considerable number (approximately 13%) of pos-
itive repeat biopsies were missed. Additional studies are
needed to identify other variables that can be used in con-
junction with PSAV and PSAD to predict the results of
repeat biopsies. In addition, although we found that when
cancer was detected at a repeat biopsy it was associated
with favorable pathological findings, it was not associated
with a better outcome following radical prostatectomy.
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